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1. Introduction  
A gastric ulcer, also called stomach ulcer, is a break in the normal gastric mucosa integrity 
that extends through the muscularis mucosa into the submucosa or deeper. The incidence 
varies with the age, gender, geographical location and is associated with severe 
complications including hemorrhages, perforations, gastrointestinal obstruction, and 
malignancy. Thus, this clinical condition represents a worldwide health problem because of 
its high morbidity, mortality and economic loss (Brown & Wilson, 1999; Dimaline & Varro, 
2007). 
The normal stomach mucosa maintains a balance between protective and aggressive factors. 
Some of the main aggressive factors are gastric acid, abnormal motility, pepsin, bile salts, 
use of alcohol and nonsteroidal anti-inflammatory drugs (NSAID), as well as infection with 
microorganisms (Helicobacter pylori and others). On the other hand, mucus secretion, 
bicarbonate production, gastroprotective prostaglandin synthesis and normal tissue 
microcirculation protect against ulcer formation. Although in most cases the etiology of 
ulcer is unknown yet, it is generally accepted that gastric ulcers are multifactorial and 
develop when aggressive factors (endogenous, exogenous and/or infectious agents) 
overcome mucosal defense mechanisms (Allen & Garner, 1980; Wallace, 1992; Peskar & 
Marici, 1998; Tulassay & Herszényi, 2010). 
In this context, the present chapter aims to address etiologies multiples of gastric ulcer 
development, clarifying how the imbalance between aggressive and defensive factors leads 
to this clinical condition. For this purpose, we review basic components of gastric mucosal 
defense and discuss conditions in which mucosal injury is directly related to impairment in 
mucosal defense. 
2. Gastric protective factors  
The stomach is lined by a complex epithelium that forms a selective barrier between the 
external environment (lumen) and the body, which is folded into several branching, tubular 
gastric glands that reach deep into the muscularis mucosa. The diverse range of functions 
performed by gastric epithelial cells is maintained in the face of a hostile luminal 
environment that can contain up to 150 mm HCl and aggressive proteases, which are 
capable of digesting tissue, as well as a variety of noxious pathogens (Dimaline &Varro, 
2007). Despite continuous exposure to these injurious factors, under normal conditions a 
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large number of defense mechanisms prevent local damage and maintain structural and 
functional mucosal integrity (Tulassay & Herszényi, 2010). 
In general, gastric defense mechanisms consist of a gastric mucosal “barrier”. It is a 
multilayer system, which include a preepithelial mucus-bicarbonate “barrier”, an epithelial 
“barrier” (surface epithelial cells connected by tight junctions), and a subepithelial 
component including blood flow and nerves. (Henriksnäs et al., 2006; Dimaline & Varro, 
2007; Nayeb-Hashemi & Kaunitz, 2009).  
2.1 Gastric mucosal “barrier” 
2.1.1 Preepithelial mucus-bicarbonate “barrier” 
The regular exposure of the stomach to endogenously produced acid and degrading 
enzymes requires the presence of an efficient gastric mucosal “barrier”. Since the first 
experimental evidence for the mucus bicarbonate barrier was reported about three decades 
ago (Allen, 1978; Allen & Garner, 1980), it has become firmly established as a key 
component of the gastroduodenal mucosal protective mechanisms against noxious agents 
(Allen & Flemström, 2005). This barrier constitutes the first line of mucosal defense and is 
formed by mucus gel, bicarbonate (HCO3▬), and surfactant phospholipids, which cover the 
mucosal surface (Lichtenberger, 1999; Allen & Flemström, 2005).  
The gastric mucus consists of a viscous, elastic, adherent and transparent gel secreted by 
apical expulsion from surface epithelial cells. It is formed by ~ 95% water and ~ 5% mucin 
glycoproteins that covers the entire gastrointestinal mucosa, and its luminal surface is 
coated with a film of surfactant phospholipids with strong hydrophobic properties. The 
HCO3▬ is secreted by surface epithelial cells and its role is to neutralize acid diffusing into a 
stable, adherent mucus gel layer and to be quantitatively sufficient to maintain a near-
neutral pH (~ 7.0) at the mucus-mucosal surface interface (Figure 1) (Hills et al., 1983; 
Lichtenberger 1999; Repetto & Llesuy, 2002; Tulassay & Herszényi, 2010).  
In contrast to stomach acid, pepsin has received relatively little attention as the other 
endogenous aggressor in gastric juice. Pepsin damage is characterized by focal areas of 
discontinuity in the adherent mucus layer, localized hemorrhagic punctuate ulcers with 
bleeding into the lumen, and no evidence of reepithelialization or mucoid cap formation 
(Allen & Flemström, 2005). Thus, the unstirred mucus gel layer is also a physical barrier to 
luminal pepsin accessing the underlying mucosa. It retains HCO3▬ secreted by surface 
epithelial cells, preventing penetration of pepsin and therefore proteolytic digestion of the 
surface epithelium (Tulassay & Herszényi, 2010). Therefore, a dissipation of the mucus gel 
and phospholipid layer by ulcerogenic substances (such as aspirin and bile salts) leads to 
both acid back-diffusion and mucosal injury. (Darling et al., 2004; Allen & Flemström , 2005). 
Moreover, if some oxygen radicals are generated in surface epithelium containing mucus, 
intracellular mucus could scavenge them, acting as an antioxidant and thus reducing 
mucosal damage mediated by oxygen free radicals. (Penissi & Piezzi, 1999; Repetto & 
Llesuy, 2002). Even when cells containing mucus are damaged by extracellular oxygen 
radicals, intracellular mucus may be released into the gastric tissue and prevent additional 
damage by scavenging them (Seno et al., 1995). 
The efficacy of protective properties of the mucus barrier depends not only on the gel 
structure but also on the amount or thickness of the layer covering the mucosal surface 
(Penissi & Piezzi, 1999; Repetto & Llesuy, 2002). The thickness of this layer is the result of a 
dynamic balance between its secretion and its erosion mechanically by shear forces of the 
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digestive process and by proteolytic degradation, particularly from luminal pepsin in 
stomach. Compared with other gastrointestinal secretions, the adherent mucus gel form is 
physically unique. Studies have shown that adherent mucus gels from stomach, duodenum, 
and colon are all well-defined viscoelastic gels that do not dissolve on dilution (Allen et al., 
1976; Allen, 1989; Allen & Flemström, 2005). They flow over a relatively long time (30–120 
min), reannealing when sectioned. Thus, mucus gels are known stable substances, and 
exposure of isolated gastric mucus gel to pH 1–8, hypertonic salt, or bile does not disperse 
or affect its rheological properties. In functional terms, these recognized properties 
contribute to the adherent mucus gel layer forming a continuous and effective protection 
over the mucosa (Allen & Flemström, 2005) 
The mucus bicarbonate barrier is the only preepithelial barrier between epithelium and 
lumen. When it is overwhelmed or breaks down in different disease conditions, the next 
series of protective mechanisms come into play, including epithelial repair, and 
maintenance and distribution of mucosal blood flow (Tulassay & Herszényi, 2010). 
2.1.2 Epithelial “barrier”  
Subsequent to mucus-bicarbonate “barrier”, the next line of mucosal protection is formed by 
a continuous layer of surface epithelial cells, which secrete mucus and bicarbonate and 
generate prostaglandins (PGs), heat shock proteins, trefoil factor family peptides (TFFs), and 
cathelicidins. This epithelial barrier serves to separate the digestive lumen from the internal 
compartments of the organism. Its main role is to maintain a selective exchange of different 
substances (secretions, nutrients, etc.) between these two compartments, and to assure the 
protection of the organism against the penetration of micro-organisms and other exogenous 
antigens, essentially contained in food. In this context, two crucial elements of the digestive 
epithelial barrier assure these functions: the epithelial cells and the intercellular junctions 
(tight junctions). Both structures provide two pathways for transepithelial transport: 
transcellular and paracellular routes, respectively (Figure 1). (Matysiak-Budnik, et al., 2003; 
Laine et al., 2008; Tulassay & Herszényi, 2010). Because of the presence of phospholipids on 
epithelial cells surfaces, these cells are hydrophobic and therefore repel acid- and water-
soluble damaging agents (Lichtenberger et al., 1983). 
The paracellular pathway seems to be the major route of transepithelial macromolecular 
permeation. This route is a complex array of structures that are mainly controlled by tight 
junctions between epithelial cells, which appear to be key regulators of gastrointestinal 
permeability to macromolecules such as endotoxin and other bacterial products. Also, 
interconnected by tight junctions, the surface epithelial cells form a “barrier” preventing 
back diffusion of acid and pepsin (Farhadi et al., 2003; Werther, 2000; Laine et al., 2008). The 
physiology of this tightly regulated conduit is not fully known. However, this dynamic 
gateway is able to change its size under various physiological and pathological conditions. 
For instance, an earlier study (Madara, 1983) showed that increases in guinea pig intestinal 
transepithelial resistance induced by osmotic loads were accompanied by alterations in 
absorptive-cell tight junction structure. This alteration in intestinal permeability after meal 
ingestion enhances the ability of the small intestine to harvest the maximal amount of 
nutrients, as well as also increase the risk of exposure to luminal proinflammatory 
compounds. Tight junctions are also composed of other structural proteins including actin 
anchoring protein (ZO-1) and occludin, which could be the target of oxidative or other toxin 
injury and result in disruption of gastrointestinal barrier integrity (Farhadi et al., 2003; 
Nusrat et al., 2001). 
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Fig. 1. Bicarbonate rich mucous secreted by surface epithelial cells.  
Heat shock proteins generated by gastric epithelial cells are essential for the maintenance of 
cellular homeostasis during normal cell growth and for survival during various cellular 
stresses, such as increased temperature, oxidative stress, and cytotoxic agents, preventing 
protein denaturation and protecting cells against injury. Activation of heat shock protein 
response is one of the mucosal protective mechanisms of the antacid hydrotalcite. Also, 
cathelicidin and ß defensins are cationic peptides that play roles in the innate defensive 
system at mucosal surfaces preventing bacterial colonization. These elements have been 
demonstrated in gastric epithelial cells, and they accelerate ulcer healing (Tarnawski et al., 
1999; Oyaka et al., 2006; Tanaka et al., 2007; Tulassay & Herszényi, 2010).  
The trefoil factor family (TFFs) comprises a group of small peptides (6.5–12 kDa) secreted 
abundantly by surface epithelium, which has been demonstrated play an important role in 
mucosal integrity (Taupin & Podolsky, 2003). They regulate reepithelialization by 
stimulating cell migration and exert mucosal protective action from a broad range of toxic 
chemicals and drugs (Laine et al., 2008), as well as inhibiting apoptosis and inflammation, 
and augmenting the barrier function of mucus (Taupin & Podolsky, 2003; Hernández et al., 
2009; Tulassay & Herszényi, 2010).  
Maintenance of epithelial integrity requires a precise balance between cell proliferation and 
cell death. Thus, the epithelium is continually renewed by a well-coordinated and controlled 
proliferation of progenitor cells that enables replacement of damaged or aged surface 
epithelial cells. In this context, the gastric epithelium is populated by a variety of 
functionally-mature cells derived from proliferation of stem cells, such as mucous cells in 
the stomach, which show rapid turnover rates, and die within only a few days after their 
formation. Cell proliferation of progenitor cells is controlled by two peptides that have 
received attention for their potential role in barrier maintenance: epidermal growth factor 
(EGF), derived from salivary, esophageal and duodenal glands, and transforming growth 
factor alpha (TGF-alpha). Both peptides stimulate epithelial cell proliferation in case of 
injury as well as also enhance mucus secretion and inhibit acid production in the stomach 
(Murphy, 1998; Laine et al., 2008). However, after superficial injury, restitution of the surface 
epithelium occurs within minutes by migration of preserved epithelial cells located in the 
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neck area of gastric glands. Such migration precedes and is independent of proliferation of 
progenitor cells, which occurs hours after injury (Lacy & Ito, 1984; Blikslager & Roberts, 
1997; Laine et al., 2008).  
Prostaglandins (PGs) are also synthesized by gastric mucosal epithelial cells from 
arachidonate metabolism through the action of cyclooxygenases (COX). The ability of 
exogenous PGs to attenuate or even completely prevent mucosal damage caused by 
corrosive substances such as absolute ethanol, concentrated bile or hiperosmolar solutions 
has been termed "cytoprotection” (Farhadi et al., 2003). Particularly prostaglandin E2 and 
prostacyclin have long been known to have "cytoprotective" effects on the gastrointestinal 
epithelium and therefore they can be crucial for the maintenance of the gastric integrity. In 
fact, it is well established that inhibition of their synthesis results in the reduction of gastric 
mucosal blood flow and gastric mucosal damage (Abdel Salam et al., 1997).  
Thus, although the precise mechanism of cytoprotective action of prostaglandins remained 
unknown, it appears to result from a complex ability to stimulate mucosal mucus and 
bicarbonate secretion, to increase mucosal blood flow and sulfhydryl compounds and, 
particularly in the stomach, to limit back diffusion of acid into the epithelium (Tarnawski et 
al., 1985; Farhadi et al., 2003; Kato et al., 2005). Earlier studies confirm not only these finding 
but also document that certain growth factors, especially EGF, could be considered as 
gastroprotective because they were capable of reducing nonsteroidal anti-inflammatory 
drugs (NSAID)-induced gastric ulcerations in animals when endogenous PGs were 
completely inhibited by administration of these drugs (Konturek et a., 1981). Also, growth 
factors stimulated prostaglandin production in rat endometrial cells through a mechanism 
that involves an increase in cyclooxygenase activity (Bany & Kennedy, 1995). Moreover, 
previous studies (Matsuda et al. 2002; Sánchez et al. 2006), including that conducted by our 
group (Silva et al., 2009), reported that endogenous prostaglandins are involved in the 
protective effect of different natural or semi-synthetic terpenes.  
In addition, other mediators such as nitric oxide (NO), calcitonin gene related peptide 
(CGRP) as well as some hormones including gastrin and cholecystokinin (CCK), ghrelin, 
leptin and gastrin-releasing peptide (GRP) have been also found to protect gastric mucosa 
against the damage induced by corrosive substances. This protective action has also been 
attributed in part to the release of PGs because it could be abolished by the pretreatment 
with indomethacin (a nonselective inhibitor of COX 1 and 2) and restored by the addition of 
exogenous PGE2 (Farhadi et al., 2003). 
2.1.3 Subepithelial components (microcirculation and sensory innervations) 
The modulation of the gastric mucosal microcirculation plays an essential role in the 
maintenance of gastric integrity, especially for delivering oxygen and nutrients and 
removing toxic substances. At the level of the muscularis mucosae, most gastric arteries 
branch into capillaries, which enter the lamina propria and travel upward in proximity to 
gastric glandular epithelial cells. At the base of surface epithelial cells, capillaries converge 
into collecting venules (Laine et al., 2008; Tulassay & Herszényi, 2010). Thus, blood flow is 
essential for many protective mechanisms. For instance, restitution, a process whereby 
denuded areas of the mucosa are covered by rapidly migrating cells from adjacent mucosa, 
depends to a large extent on adequate blood flow (Lacy & Ito, 1984; Guttu et al., 1994; 
Abdel-Salam et al., 2001). Also, exposure of the gastric mucosa to an irritant or acid back-
diffusion occurrence leads to a marked increase in mucosal blood flow. This increase allows 
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removal and/or dilution of the back-diffusing acid and/or noxious agents and seems to be 
essential for mucosal defense because its abolition through mechanical restriction of blood 
flow leads to hemorrhagic necrosis (Holzer, 2006, Laine et al., 2008).  
The endothelial cells are also able to generate potent vasodilators agents such as nitric oxide 
(NO) and prostacyclin (PGI2). NO is produced from L-arginine in a reaction catalyzed by 
the enzyme nitric oxide synthase (NOS) (Bredt & Snyder, 1990). It is an important biological 
signaling molecule that influences circulation by regulating vascular smooth muscle tone 
and modulating systemic blood pressure. Therefore, it has been shown to exert positive 
effects on mucosal defense in the gastrointestinal system (Berg et al., 2004). Both NO and 
PGI2 oppose the mucosal damaging action of vasoconstrictors such as thromboxane A2, 
leukotriene C4, and endothelin. Consequently, these agents maintain viability of endothelial 
cells and prevent platelet and leukocyte adherence to the microvascular endothelial cells, 
preventing compromise of the microcirculation and thus protecting the gastric mucosa 
against injury (Laine et al., 2008). In addition to maintaining gastric blood flow, NO protects 
the gastrointestinal tract by inhibiting gastric acid secretion from parietal cells, stimulating 
mucus and bicarbonate secretion and by promotion angiogenesis in vivo and in vitro (Brown 
et al., 1993; Ma and Wallace, 2000). 
Thus, for all its functions on gastric mucosal, NO has been shown to be beneficial in gastric 
ulcer healing. In fact, previous studies have demonstrated that NOS inhibition by N(G)-
nitro- L-arginine (L-NNA) or N(G)-monomethyl-L-arginine (L-NMMA) significantly 
delayed ulcer healing, impaired angiogenesis in the granulation tissue and reduced gastric 
blood flow around the ulcer (Konturek et al., 1993). Also, NOS inhibitor N(G)-nitro-L- 
arginine methyl ester (L-NAME) has been showed to increase ethanol-induced gastric 
lesions in mice (Bulut et al., 1999; Silva et al., 2009). On the other hand, administration of an 
NO donor (glyceryl trinitrate) or L-arginine (the substrate of NOS) significantly reverses 
NOS inhibitor induced delayed healing and enhances healing (Elliott et al., 1995; 
Brzozowski et al., 1995; Moura Rocha et al.; 2010). 
In addition to local mucosal protection factors, gastric mucosal defense is also regulated, at 
least in part, by the central nervous system and hormonal factors (Stroff et al., 1995; Peskar, 
2001; Mózsik et al., 2001). Gastric mucosa and submucosal vessels are innervated by primary 
afferent sensory neurons and nerves forming a dense plexus at the mucosal base. Afferent 
neurons constitute an emergency system that is requested when the gastric mucosa is 
endangered by noxious agents. Thus, activation of these nerves in presence of gastric acid 
promotes releasing of neurotransmitters such as substance P and calcitonin gene-related 
peptide (CGRP), which relax the smooth muscle surrounding the arterioles, resulting in an 
elevation of mucosal blood flow, increase in mucus gel and surface cell intracellular pH in 
stomach. This mucosal protective action occurs most likely through vasodilatation of 
submucosal vessels mediated by NO generation. In this sense, interference with any aspect 
of the sensory innervations impairs the hyperemic response and therefore diminishes 
resistance of the gastric mucosa to injury (Tanaka et al., 1997; Holzer, 2007; Laine et al., 2008; 
Tulassay & Herszényi, 2010).  
3. Etiologies multiples of gastric ulcer development 
Despite its robust and multi-faceted nature, many factors directly related to impairment in 
mucosal defense can alter the epithelial barrier and encourage the formation of mucosal 
injury, the most important of which are acid secretion, bacteria and their products, non-
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steroidal anti-inflammatory drugs, alcohol, reactive oxygen species, as well as different 
chemical compounds. Their effects on the gastric barrier represent important mechanisms of 
the pathogenesis of gastric ulcers, chronic gastritis and other gastric diseases, which are 
frequently generated through an imbalance between mucosal aggressive and defensive 
factors (Figure 2) (Wallace, 1992; Peskar & Marici, 1998; Tulassay & Herszényi, 2010). 
 
 
Fig. 2. (A) Healthy gastric mucosa: balance between mucosal aggressive and protective 
factors. (B) Gastric ulcer formation: imbalance between mucosal aggressive and protective 
factors.  
3.1 Helicobacter Pylori  
Helicobacter pylori is a common human pathogen and public health problem associated with 
the pathogenesis of gastritis and peptic ulcers. With a prevalence of up to 90% in developing 
populations, this microorganism is the second most common pathogen for human beings. It 
is a nonsporulating, gram-negative microaerophilic bacilli, spiral-shaped, having one to six 
polar-sheathed flagellae emerging from one of its rounded ends and a smooth surface (Dye 
et al.; 1989). This pathogen multiplies with great efficiency in the hostile environment within 
the stomach but survives poorly in the gastric lumen. It is mainly found under the mucous 
layer and in close proximity, or even attached, to gastric superficial epithelial cells, without 
substantial invasion of host tissue (Dubois, 1995). 
H. pylori induces chronic gastritis of varying severity in infected subjects, which in around 
10-15% progresses to peptic ulcer, while in 1-2% of subjects ultimately results in MALT 
lymphoma or gastric adenocarcinoma. The initial response to infection is an interaction of 
the host epithelial cells with the bacteria, however, the pathogenetic mechanisms of chronic 
infection with H. pylori and gastric ulcer are yet to be full determined (Parsonnet et al., 1991; 
Ernst & Gold, 2000; Calvino-Fernández & Parra-Cid, 2010).  
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A characteristics feature of this pathogen is the synthesis of urease, which was its first 
virulence factor studied. This enzyme may explain the extraordinary ability of bacteria to 
colonize the gastric mucosa and survive in an acid environment (Smoot, 1991). Because the 
ecologic niches of these bacteria are rich in urea, it catalyzes urea hydrolysis with the 
formation of ammonium (NH3), carbon dioxide and hydroxyl ions. By this mechanism, H. 
pylori neutralizes the surrounding gastric acid and protects itself from the strong acidicity of 
the stomach (Smoot, 1991). On the other hand, although the neutralization of gastric acid 
benefits the bacteria, metabolites from urease activity are toxic to gastric epithelial cells 
(Figure 3). The formed ammonium reacts with OCl- produced by activated neutrophils to 
form highly toxic monochloramine (NH2Cl) in the stomach, a hallmark of H. pylori infection. 
In fact, inhibition of H. pylori urease has been showed significantly decrease this toxicity, 
suggesting that ammonia is at least partially responsible for the cytotoxicity found in 
association with this bacterium. Moreover, hydroxide ions are also considered toxic to 
gastric epithelial cells (Smoot, 1991; Handa et al., 2010). 
Besides urease activity, further important virulence factors from H. pylori are their spiral 
shape and the motility of their flagellae, which render them resistant to peristaltic flushing 
of the gastric contents and enable them to persist in the mucous layer. Additionally, this 
pathogen produces other enzymes including catalase, oxidase, protease, and phospholipase, 
as well as it synthesizes specific adhesion proteins that enable them to adhere to mucous 
and epithelial cells (Boren et al., 1993; Dubois, 1995). In this context, although H. pylori 
typically colonizes the human stomach for many decades without adverse consequences, as 
referred above, the presence of this pathogen is associated with an increased risk of several 
diseases, including peptic ulcers, noncardia gastric adenocarcinoma, and gastric mucosa 
associated lymphoid tissue (MALT) lymphoma (Cover & Blaser, 2009).  
The risks of developing gastric diseases are determined in part by the presence or absence of 
specific genotypes of the H. pylori strains with which an individual is colonized. For that 
reason, H. pylori pathogenicity may differ with respect to each of its virulence factors and 
this diversity is likely to contribute to variation in colonization or disease. (Dubois, 1995; 
Marshall & Windsor, 2005; Cover & Blaser, 2009). Thus, a number of H pylori strains can 
express multiple factors that interact with host tissue and therefore are associated with 
increased gastric mucosal inflammatory cell infiltration and increased gastric epithelial 
injury, whereas strains that lack these factors would be relatively noninteractive with the 
host. When virulent H. pylori strains are present, organisms adhere to the gastric epithelium, 
which disrupts membrane integrity and induces host cells to release toxic proteins, 
cytotoxins, platelet activating factor, , and lipopolysaccharides that all further damage the 
gastric mucosa. These changes would accelerate apoptosis and proliferation in the mucosal 
layer (Figure 3) (Crabtree, 1996; Kohda et al., 1999; Makola et al., 2007). However, it has been 
shown that this inflammation resolves after eradication of the infection, and presumably the 
concentrations of the pro-inflammatory and antisecretory cytokines also decrease. Thus, 
once the eradication of the bacterium is always followed by resolution of gastritis, the aim of 
treatment is eradication of the pathogen, defined as negative tests for the organism for one 
month after completion of the course of the antimicrobial (Pakodi et al., 2000; Kuipers et al., 
2003; Brzozowski, et al., 2006). 
Although much research and understanding have been gained in the last decades since the 
discovery of H. pylori, more questions have been raised than answered. The long road 
towards deciphering the fundamental mechanisms underlying the development of gastritis, 
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intestinal metaplasia and gastric cancer has only just begun. Thus, currently it is apparent 
that infection with H. pylori negatively influences several of the important defense 
mechanisms in the gastric barrier, however, the exact mechanisms leading to the 
development of pathological changes by H. pylori remain to be further investigated. 
 
 
Fig. 3. Gastric ulcer formatted by Helicobacter pylori. (1) H. pylori catalyzes urea hydrolysis 
with the formation of ammonium (NH3) that neutralizes the surrounding gastric acid and 
protects itself from the strong acidicity of the stomach. (2) H. pylori penetrates the mucus 
layer of stomach, adhere the surface of gastric mucosal epithelial cells, prolifirate and finally 
form the infectious focus. The gastric lesion is developed by destruction of mucosa, 
inflammation and mucosal cell death. 
3.2 Non-steroidal anti-inflammatory drugs (NSAIDs)  
Another important factor directly related to gastric injury initiated by impairment in 
mucosal defense is the prominent non-steroidal anti-inflammatory drugs (NSAIDs) use. As 
the prevalence of H. pylori infection has declined, because of continued efforts to eradicate 
the organism, the prevalence of NSAID-induced ulcers has risen and is taking on greater 
clinical importance. Studies show that NSAIDs are among the most commonly used drugs 
in the world. In United States, approximately 70 million prescriptions are written each year, 
while in Europe these medications represent more than 7.7% of all prescriptions (Graumlich, 
2001; Jones, 2001). NSAIDs use is more frequent among women and increases with age, as 
does the incidence of rheumatic diseases. In fact, more than 90% of prescriptions for NSAIDs 
are made to patients aged >65 years. The major problem with the use of these drugs is that 
they induce predictable gastric mucosal injury, including complications in both upper and 
lower gastrointestinal tract (Laine et al., 2008; Sostres et al., 2010). 
The major mechanism via which NSAIDs cause ulcers and gastrointestinal complications is 
thought to be by inhibition of cyclooxygenase (COX), a key enzyme in the biosynthesis of 
prostaglandins (PGs). There are two well identified isoforms of COX, COX 1 and COX 2 
(Laine et al., 2008; Sostres et al., 2010). COX 1 isoform is expressed in most tissues, 
producing prostaglandins that play an essential protective role in the stomach by 
stimulating the synthesis and secretion of mucus and bicarbonate, increasing mucosal blood 
flow and promoting epithelial proliferation. So, the COX-1-mediated PG synthesis is mainly 
responsible for maintaining gastric mucosal integrity at baseline. On the other hand, COX2 
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has little or no expression in most tissues but is rapidly induced in response to inflammatory 
stimuli. Therefore, this isoform is the primary target for anti-inflammatory drugs.  
In this context, the traditional NSAIDs nonselective inhibitors of both COX-1 and COX-2, 
such as indomethacin or ibuprofen, cause damage in the stomach with a marked decrease in 
the gastric mucosal PGE2 content. This effect occurs via COX 1 isoform inhibition, creating a 
gastric environment that is more susceptible to topical attack by endogenous and exogenous 
factors (Vane & Botting, 1995). Moreover, the inhibition of the COX 1 blocks platelet 
production of thromboxane, which increases bleeding when an active gastrointestinal 
bleeding site is present (Lanas & Scheiman, 2007; Sostres et al., 2010). This contention was 
further supported by the fact that COX-2 selective inhibitors, which do not inhibit COX-1 at 
therapeutic doses, do not affect the mucosal PGs production and do not produce gross 
gastric damage in experimental models (Laine et al., 2008).  
Therefore, the development of NSAIDs which selectively inhibit COX-2 (Coxibs), while 
having little to no effect on COX-1, should result in effective pain relief with reduced 
adverse gastrointestinal effects. In fact, data from large gastrointestinal outcomes studies 
reveal that Coxibs significantly decrease gastroduodenal ulcers as compared with 
nonselective NSAIDs. Ulcer rates were significantly decreased with 5 tested Coxibs 
(celecoxib, valdecoxib, rofecoxib, lumiracoxib, etoricoxib) and when these drugs were tested 
against any of the most commonly used NSAIDs (diclofenac, naproxen or ibuprofen) 
(Rostom et al., 2007). Large randomized controlled outcome trials demonstrate a 
considerable reduction in upper gastrointestinal complications and overall upper 
gastrointestinal clinical events with Coxibs compared to traditional NSAIDs (Silverstein et 
al., 2000; Laine et al., 2007). Moreover, the results of another large outcomes study, celecoxib 
vs naproxen and diclofenac in osteoarthritis patients, confirmed the significantly better 
safety profile of celecoxib compared with traditional NSAIDs (Singh et al., 2006).  
However, has been recognized that prostaglandins derived from COX-2 can be generated at 
the ulcer margin and appear to play an important role in ulcer healing through triggering 
the cell proliferation, promotion of angiogenesis and restoration of mucosal integrity 
(Konturek et al., 2005, Sostres et al., 2010). These observations indicate that, in contrast to the 
initial concept, COX-2 plays an important role in gastric mucosal defense. Accordingly to 
this, experimental studies have reported that inhibition of both COX-1 and COX-2 is 
required for NSAID-induced gastric injury (Wallace et al., 2000; Tanaka et al., 2001; Peskar et 
al., 2001) and therefore Coxibs markedly decrease but do not eliminate NSAIDs associated 
gastric and duodenal ulceration (Silverstein et al, 2000; Sostres et al., 2010). In fact, 
indomethacin and similar NSAIDs, which inhibit both isoforms of the COX enzyme, 
produce more severe damage in gastric tissue, even gastrointestinal bleeding, than more 
selective drugs (Delaney et al., 2007). Therefore, indomethacin became one of the first choice 
drugs to produce an experimental ulcer model (Sigthorsson et al., 2000; Suleyman et al., 
2004). In this sense, the fact that nimesulide, which is considered to be less selective for 
COX-2 compared to Coxibs, is able to inhibit NSAID-induced gastric damage, while Coxibs 
agents (more selective for COX-2) are unable to inhibit these ulcers, indicates that it is 
impossible to attribute the gastrointestinal side effects of indomethacin and other NSAIDs to 
the inhibition of only the COX-1 enzyme (Suleyman et al., 2002). 
In addition, studies have evidenced that NSAIDs may induce tissue and cell injury by 
mechanisms independent of prostaglandin inhibition, which include the inhibition of 
phosphorylating enzymes (kinases), inhibition of oxidative phosphorylation in 
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mitochondria, and/or activation of apoptosis (Husain et al., 2001). These mechanisms, in 
combination with those related to prostaglandin suppression, lead to microvessel occlusion 
and subsequent hyperproduction of reactive oxygen metabolites. Such agents are then able 
to induce oxidative tissue injury that seems to play a prominent role in the development of 
mucosal ulceration caused by NSAIDs (Blandizzi et al., 2005). Furthermore, with the 
decrease in arachidonic acid metabolism via the COX pathway in NSAID users, arachidonic 
acid metabolism may be shifted to the alternative 5-lipoxygenase pathway, with a resultant 
increase in leukotriene production. In this way, a potential role for leukotrienes in NSAID 
induced gastric injury also has been postulated, since licofelone, an inhibitor of COX-1, 
COX-2, and 5-lipoxygenase, did not increase gastric mucosal injury (Bias et al., 2004).  
Thus, because the prevalence and severity of NSAID-related gastrointestinal complications, 
recent efforts have been directed at the prevention of mucosal injury induced by these 
agents. In this sense, since NSAID and even Coxibs therapy delay the healing of active 
peptic ulcers, the best way to prevent mucosal injury is to avoid the use of NSAIDs or 
replace it with an agent less toxic to the gastroduodenal mucosa (Sostres et al., 2010). 
3.3 Gastric acid secretion  
For decades, surgeons were taught and believed that peptic ulcer disease was caused by 
acid, since the cure rate of peptic ulcer disease by acid-reduction operations (such as partial 
gastrectomies, gastroenterostomies or vagotomies) was substantial, impressive, and 
reported in the literature repeatedly, as described by Latarjet (1922) and Herrington et al. 
(1984). Thus, acid was meticulously measured in an attempt to better understand and treat 
peptic ulcer disease, the major clinical challenge at that time (Dotevall & Walan, 1971). In 
this sense, when pharmacologic means were developed such as histamine-2 blockers drugs 
(like cimetidine), which effectively eliminated acid and thus many patients found that their 
ulcer disease was healed, these observations validated the dictum “no acid, no 
ulcer”(Gustafson and Welling, 2010).  
Over time, the prevalence as well as the management of these disorders has changed. With 
the advent of newer pharmacological therapy (potent antisecretory medications such as 
proton pump inhibitors) and the understanding of the role of Helicobacter pylori in the 
pathogenesis of peptic ulcer disease, more ulcers were successfully treated medically and 
the number of surgical cases drastically decreased (Lorentzon et al., 1987; Lindberg et al., 
1990; Meyer-Rosberg et al., 1996; Fock et al., 2008; Schubert & Peura, 2008). As a result, the 
quantitative measurement of gastric acid secretion, for the most part, has become obsolete. 
Nevertheless, although there are multiple processes involved in the development of gastric 
lesions, the presence of acid hypersecretion continues to be a necessary condition for ulcer 
production and for a variety of common gastrointestinal disorders, since medical therapy 
for these illnesses involves both removing the injurious agent (eg, NSAIDs or H. pilory) and 
inhibiting acid secretion (Richardson et al., 1998; Schubert & Peura, 2008). 
Parietal cells secrete hydrochloric acid at a concentration of approximately 160 mmol/L or 
pH 0.8. Acid facilitates the digestion of proteins and absorption of calcium, iron, and 
vitamin B-12, as well as it is the first line of mucosal defense to avoid microorganisms 
colonization thus preventing the bacterial overgrowth and consequent enteric infection 
(such as by Helicobacter pylori). However, when levels of acid (and pepsin) overwhelm 
mucosal defense mechanisms, common and potentially serious acid-related clinical 
conditions occur, including gastroesophageal reflux disease, Barrett's esophagus, where the 
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usual squamous mucosal lining becomes replaced by columnar epithelial cells of putative 
specific aspect, peptic ulcer disease, and stress-related erosion/ulcer disease (Schubert & 
Peura, 2008; Schubert, 2008).  
Acid is thought to gain access to the lumen by means of channels in the mucus layer created 
by the relatively high intraglandular hydrostatic pressures generated during secretion 
(approximately 17 mm Hg) (Johansson et al., 2001). Thus, luminal acid interferes with the 
process of restitution, resulting in the conversion of superficial injury to deeper mucosal 
lesion and inactivates the acid-labile growth factors important for maintenance of mucosal 
integrity and repair of superficial injury. A large amount of studies show that the rate of 
acid secretion by the human stomach changes little with aging unless there is coexisting 
disease of the oxyntic mucosa such as atrophic gastritis, infection with H. pylori or both 
(Trey et al., 1997; Schubert & Peura, 2008). 
To prevent acid-induced mucosal damage, gastric acid must be precisely regulated through 
a highly coordinated interaction of neural, hormonal, and paracrine pathways (Schubert & 
Peura, 2008). In this sense, the principal stimulants of acid secretion include gastrin, 
histamine, gastrin-releasing peptide (GRP), orexin, ghrelin, and glucocorticoids, while the 
main inhibitor is somatostatin, released from oxyntic and pyloric D cells (paracrine). 
Gastrin, released from antral G cells into the blood stream during meals, stimulates acid 
secretion primarily by releasing histamine from histaminesecreting enterochromaffin-like 
(ECL) cells. GRP, released from antral nerve fibers in response to proteins, stimulates gastrin 
secretion. Ghrelin and orexin appear to stimulate acid secretion, although their physiologic 
roles in the stomach are not known. Glucocorticoids stimulate acid secretion acting via 
phosphoinositide 3 kinase, serum-inducible kinase and glucocorticoid-inducible kinase 
(Schubert, 2008). In addition, acetylcholine (Ach), released from postganglionic enteric 
neurons (neuronal stimulation), acts directly stimulating parietal cell acid secretion, as well 
as indirectly, by eliminating the inhibitory paracrine influence of somatostatin on parietal 
and ECL cells (Chuang et al., 1993; Schubert, 2008; Schubert & Peura, 2008).  
Acid secretion by the parietal cell involves intracellular elevation of calcium, cyclic AMP, or 
both followed by a cascade that triggers the translocation of the proton pump, H+K+-
ATPase, from cytoplasmic tubulovesicles to the apical plasma membrane. This pump is an 
integral membrane protein that transports hydronium ions from the cytoplasm into the 
canaliculus of the parietal cell in exchange for potassium. Most of the adult population 
chronically infected with H. pylori produce less than normal amounts of acid probably due 
to increased apoptosis via secreted mediators (such as VacA cytotoxin and 
lipopolysaccharide), induction of proinflammatory mediators (such as IL-1b), and inhibition 
of the H+K+-ATPase activity (Schubert, 2008). This condition may cause further reduction of 
acid production and, eventually, atrophy of the stomach lining, which may lead not only 
gastric ulcer but also increased risk for stomach cancer (Suerbaum & Michetti, 2002; Peek & 
Crabtree, 2006). Conversely, approximately 10% to 15% of patients chronically infected with 
this pathogen have antral predominant inflammation and are predisposed to duodenal 
ulcer. They produce increased amounts of acid as a result of reduced antral somatostatin 
content and elevated basal and stimulated gastrin secretion. Gastrin stimulates the parietal 
cells in the corpus to secrete even more acid into the stomach lumen and chronically may 
cause the number of parietal cells to also increase. The increased acid load ulcerations the 
duodenum (El-Omar, 2006; Schubert & Peura, 2008). 
Thus, dosed before mealtime, proton pump inhibitors drugs are the most effective acid 
inhibitors currently available and are the most widely prescribed class of gastrointestinal 
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medications. Not only can peptic ulcers be healed more rapidly with these agents, but 
refractory ulcers have all but disappeared. However, many clinical studies do support an 
accelerating effect of proton pump inhibitors on the development of atrophic gastritis in H. 
pylori-positive patients, while other evidences suggest that long-term acid suppression 
would result in relatively greater bacterial colonization in the corpus leading to diffuse or 
corpus-predominant gastritis or to acute gastroenteritis (Moayyedi et al., 2000; Rosh & 
Hassall, 2006; Schubert, 2008). Such observations have important implications given the 
extensive use of these drugs worldwide. Thus, continued progress in understanding of 
gastric acid secretion in health and disease is needed and this knowledge will be used to 
develop new more effective strategies to prevent and manage gastric disorders. 
3.4 Alcohol 
Throughout the world, alcohol has been used for centuries in social, medical, cultural, and 
religious settings. Currently, it is considered to be one of the most commonly abused drugs, 
related to a wide range of physical, mental, and social harms, and responsible for 3.8% of 
deaths and 4.6% of disability-adjusted life years lost worldwide. The World Health 
Organization (WHO) has estimated that there are about 2 billion people worldwide who 
consume alcoholic beverages and 76.3 million with diagnosable alcohol use disorders 
(Stermer, 2002; WHO, 2004, 2008; Rehm et al., 2009).  
Among the various organ systems that mediate alcohol’s effects on the human body and its 
health, the gastrointestinal tract plays a particularly important role. The alcohol absorption 
into the bloodstream occurs throughout the gastrointestinal tract and its direct contact with 
the mucosa can induce numerous metabolic and functional changes. These alterations may 
lead to marked mucosal damage, which can result in a broad spectrum of acute and chronic 
diseases, such as gastrointestinal bleeding and ulcers (Bode & Bode, 1997). In this context, 
pathogenesis of ethanol-induced gastric lesions is complex. Alcohol may interact directly 
with the gastric mucosa or it may act through a more general mechanism affecting the 
release of hormones and the regulation of nerve functions involved in acid secretion (Bode 
& Bode, 1997; Chari et al. 1993).  
Intragastric application of absolute ethanol has long been used as a reproducible method to 
induce gastric mucosa lesions in experimental animals (Szabo et al., 1981; Arafa & Sayed-
Ahmed, 2003). The effects of acute administration of absolute ethanol to rats and mice on the 
gastric mucosa are dose-dependent and the damage appears as early as 30 minutes after 
ingestion and reaches a peak at about 60 minutes. The ethanol-induced gastric musosal 
lesions and erosions are similar to those occurring in gastric ulcer (Stermer, 2002; Repetto & 
Llesuy, 2002). Thus, alcoholic gastritis leads to the impairment of the integrity of gastric 
mucosal barrier, contributing to acid reflux into the subluminal layers of the mucosa and 
submucosa (Oh et al., 2005). 
 Chari et al. (1993) relate that intravenous, oral, and intragastric alcohol at a concentration of 
up to 5% increases acid secretion principally by stimulating the secretion of gastrin and to a 
lesser extent by a direct effect on the parietal cells. On the other hand, an alcohol 
concentration of higher than 5% has no effect on gastric acid secretion (Stermer, 2002). Also, 
oxidative stress and depletion of non-protein sulfhydryls concentration, modulation of nitric 
oxide system and reduction of gastric mucosal blood flow frequently underlie the 
development of gastric lesions (Arafa & Sayed-Ahmed, 2003). According to Bode et al. 
(1996), the decreased formation of prostaglandins might also play a role in alcohol-induced 
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mucosal injury, while other studies have indicated that an alcohol-dependent increase in the 
production of leukotrienes also might contribute to the development of alcohol-induced 
damage. It is important emphasize that changes induced by short-term exposure to alcoholic 
beverages are rapidly reversible while prolonged alcohol exposure leads to progressive 
structural mucosal damage (Bode & Bode, 1997). 
Oxidative stress and depletion of anti-oxidants have been considered a crucial step in 
alcohol-induced mucosal damage and so they have been widely investigated in a number of 
studies (Hirokawa 1998; La Casa et al., 2000; Arafa & Sayed-Ahmed, 2003). Ethanol 
treatment induces intracellular oxidative stress and produces mitochondrial permeability 
transition and mitochondrial depolarization, which precede cell death in gastric mucosal 
cells. Thus, considering that ethanol is involved in the formation of oxidative stress 
generated extracellularly and/or intracellylary, the cytoprotective role of anti-oxidants in 
the prevention and healing of gastric lesions has also been widely investigated (Santos & 
Rao, 2001; Silva et al., 2009). In this sense, various studies point to intracellular antioxidants, 
such as glutathione (an endogenous sulfhydryl compound, as described below), as 
significant protective agents against ethanol in gastric mucosal cells (Repetto & Llesuy, 
2002). Intragastric administration of superoxide dismutase was also able to protect the 
gastric mucosa against the damaging effect of ethanol (Terano et al., 1989). Also, ethanol-
induced oxidative stress may account for the decreased NO release, because NO may be 
shunted toward scavenging free radicals. In this context, response to ethanol was prevented 
by increased production of nitric oxide and inducible NOS (Kato et al., 2000). In addition to 
ethanol-induced gastrointestinal tract alterations, alcohol consumption has been linked to 
increased risk of tumors in the pharynx, esophagus, stomach and colon (Stermer, 2002). 
3.5 Oxidative stress 
It is well documented in the literature that reactive oxygen species (ROS), such as 
superoxide anions, hydrogen peroxide, and hydroxyl radicals, are involved in the etiology 
and physiopathology of several human diseases including neurodegenerative disorders, 
viral infections, inflammation, autoimmune pathologies, as well as in digestive disturbances 
such as gastrointestinal inflammation and gastric ulcer (Repetto & Llesuy, 2002). 
During gastric oxidative stress, the imbalance of aggressive and defensive factors in the 
stomach plays a pivotal role in gastric hemorrhage and ulcer formation (Hung, 2005). 
Overproduction of ROS has been concerned as one of the major pathogenic factors that 
directly results in oxidative damage, including lipid peroxidation, protein oxidation, and 
DNA damage, which can lead to cell death. Additionally, these agents are known to act as 
second messengers to activate diverse redox-sensitive signaling transduction cascades, 
including mitogen-activated protein kinases (MAPKs) and downstream transcription factors 
such as NF-kB and AP-1, which regulate the expression of several pro-inflammatory genes 
and, thereby, lead to the elaboration of chemical and humoral mediators of tissue 
inflammation and injury (Sun & Oberley, 1996; Ali & Harty, 2009). This is frequently 
evidenced by pro-ulcerative factors in the stomach and gut such as H pylori, use of NSAIDs, 
ethanol, smoking, psychological stress, corticosteroid use, and loss of sleep, while defensive 
factors involve glutathione (GSH), an important endogenous sulfhydryl compound, and 
mucus biosynthesis (Hung, 2005; Olaleye et al., 2007). 
In the illness state, oxidative stress of the stomach may occur and result in an elevation of 
mucosal lipid peroxide that are generated from the reaction of oxyradicals and cellular 
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polyunsaturated fatty acid, while GSH may act to prevent this aggressive action that can 
damage gastric mucosal cells. Malondialdehyde (MDA) is an end product resulting from 
peroxidation of polyunsaturated fatty acids and related esters within cell membranes, and 
the measurement of this substance represents a suitable index of oxidative tissue damage. 
On the other hand, sulfhydryl compounds such as GSH are involved in the maintenance of 
gastric integrity, particularly when reactive oxygen species are implicated in the 
pathophysiology of tissue injury (Blandizzi et al., 2005). Thus, the appearance of lipid free 
radicals and MDA in the blood and gastric juice could result from ROS-initiated chain 
reactions or initiated by indirect mechanisms that suppress the antioxidant capacity in both 
blood and gastric wall to scavenge ROS (Dotan et al., 2004; Tuorkey & Abdul-Aziz, 2011). In 
fact, numerous studies have demonstrated a decrease in GSH level in inflammatory and 
ulcerated gastric mucosa, as well as the protective effect of GSH on gastric damage induced 
by ethanol, nonsteroidal anti-inflammatory drugs, or lipopolysaccharide has been well 
documented (Hung, 2000; Hung, 2005; Silva et al., 2009; Al-Hashem, 2010). 
On the other hand, a large body of research in both animal and human studies has examined 
the effect of psychological stress on the gastrointestinal tract. For instance, in accordance to 
Levenstein et al., (1999), susceptibility to gastric lesions is increased in rats by social 
stressors as premature separation of the rat pup from its mother (Ackerman et al., 1975). 
Also, subjects with psychological distress, self-described “stress or strain,” or concrete life 
stressors at baseline have increased incidence of ulcer over 9 to 15 years (Levenstein et al., 
1995; Levenstein et al., 1999). In this sense, according to Chang (2008), stressors can be acute 
or chronic and range from daily hassles to life-threatening situations like natural disasters 
and violence that trigger the “fight or flight” response. Over time, recurrent stress results in 
an increase demand on physiologic systems. Thus, several terms have been used to describe 
stress-related mucosal damage in critically ill patients, including stress ulcers, stress 
gastritis, stress erosions, hemorrhagic gastritis, erosive gastritis, and stress-related mucosal 
disease (Ali & Harty, 2009). 
Stimulation of gastric acid secretion has historically been considered a mechanism by which 
physiological stress increases susceptibility to gastroduodenal ulceration. It is also known to 
modify gastric blood flow, which plays an important role in the gastric mucosal barrier, and 
to affect possible mediators such as cytokines, corticotropin-releasing hormone and 
thyrotropin- releasing hormone. Furthermore, stress seems to have different effects on 
gastric motility including delayed gastric emptying, which could increase the risk of gastric 
ulcer, while accelerated emptying could increase the net acid load delivered to the 
duodenum, enhancing the risk of duodenal ulcer. Psychological stress may also promote the 
growth of H. pylori in the duodenum if it increases duodenal acid load, since the H. pylori–
inhibitory effects of bile seem to be reversed by acid (Levenstein et al., 1999).  
4. Conclusion  
Despite continuous exposure to several noxious factors, under normal conditions the gastric 
mucosa is able to maintain structural integrity and function. However, gastric mucosal 
injuries may occur when harmful factors overcome an intact mucosal defense or when the 
mucosal defensive mechanisms are impaired. Thus, much importance is attached to 
interactions and relationships among various ulcer-related factors, as well as to the 
individuality of the patients, including infections by H. pylori, alcohol and NSAIDs 
consume, and even smoking use, or stress-related disease.  
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Significant knowledge over the past three decades regarding gastric mucosal attack and 
defense mechanisms has led to the development of current and potential future therapies to 
reduce gastrointestinal injury and improve the quality of ulcer healing. Therefore, the 
incidence of gastric ulcers has declined, possibly as a result of the increasing use of proton 
pump inhibitors and decreasing rates of Helicobacter pylori infection. However, although 
there are many studies on gastroprotective therapies, their clinical effectiveness remains 
unclear. Thus, because gastric ulcer is a multifactorial disease, its medical management 
should not be based on a simple cause-effect relationship, instead a bio-psychosocial 
approach adjusted for the individual patient should be applied, with careful consideration 
of the association of this disease with many personal factors. 
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